# Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct06800313/  
OnCo record `nct06800313` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JNJ-101556143 Formulation 1 in prostate cancer, run by Janssen Research & Development, LLC, now recruiting.

## Summary

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT06800313 by Janssen Research & Development, LLC, with 190 participants planned, started 2025-02-06 and due to reach its primary completion in 2028-07-11. Interventions recorded: JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2 and JNJ-101556143 Formulation 3.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06800313
- Phase: 1/2
- Setting: Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 190

## Sources

- ClinicalTrials.gov NCT06800313: https://clinicaltrials.gov/study/NCT06800313

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct06800313.json